Pharmaceutical Industry Today
IgA Nephropathy (IgAN) Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | Aravive, Novartis, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, Aduro BioTech, Alnylam Pharmaceuticals
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the IgA Nephropathy market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Additionally, the report delves into emerging therapies for IgA Nephropathy, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for IgA Nephropathy, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of IgA Nephropathy management.
Learn How the IgA Nephropathy Market is Evolving with the Ongoing Developments @ IgA Nephropathy Market Outlook
IgA Nephropathy: An Overview
IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys and affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the kidneys’ filtering unit (glomerulus).
The Oxford Classification of IgA nephropathy (IgAN) is the most widely accepted system for assessing histologic findings in IgAN. The classification indicated that only three reproducible variables were seen on the renal biopsy in IgAN that independently predicted outcome and provided prognostic information in addition to prognosis prediction given by clinical features alone.
The diagnosis of IgAN relies on revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium by kidney biopsy. Although renal biopsy remains the gold standard for IgAN diagnosis, recent efforts have sought new biomarkers to predict IgAN without needing a biopsy. However, unclear pathogenesis complicates noninvasive diagnosis.
Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. Other treatments include corticosteroids to slow the progression of the disease and other immunosuppressants like mycophenolate mofetil (MMF), cyclophosphamide, etc.
The IgAN treatment space is estimated to experience significant changes during the forecast period, owing to the launch of upcoming novel therapies and a robust pipeline of drugs developing to manage IgAN. However, the challenges of pricing, reimbursement, and associated side effects are two major factors likely to influence the market success of the upcoming therapies.
IgA Nephropathy Market Key Facts
- Among EU4 countries, Germany accounted for the maximum market size in 2022, while Spain occupied the bottom of the ladder.
- The total number of prevalent cases of IgA Nephropathy in the United States was around ~193,700 cases in 2022.
- Among the EU4 countries, Germany accounted for the largest IgA Nephropathy prevalent cases, followed by France, whereas Spain accounted for the lowest number of prevalent cases in 2022.
- Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.
Get Exclusive Data and Key Insights Shaping the Market Dynamics @ IgA Nephropathy Market Trends
IgA Nephropathy Therapeutics Analysis
The mainstay of therapy in IgA Nephropathy is optimized supportive care, which includes measures to lower blood pressure, reduce proteinuria, reduce lifestyle risk factors, and assist in reducing non-specific kidney insult. The value of immunosuppression has become debatable; if at all, systemic high-dose corticosteroid treatment for a few months should be considered, taking into account patient characteristics that would warn against or preclude such therapy. Furthermore, as GFR decreases, AEs associated with corticosteroid treatment significantly increase. Except for mycophenolate mofetil in Asian patients, there is little proof that any additional immunosuppression is beneficial beyond corticosteroids.
There are only two FDA-approved treatments for managing IgAN. Though recent drug approvals provide novel treatment choices for IgAN, there is still a high demand in the IgAN therapeutic landscape for more efficacious and targeted therapies. According to our analysis, the IgAN treatment space will undergo significant changes during the forecast period, due to the launch of upcoming novel therapies and a robust pipeline of drugs in development for the treatment of IgAN.
Improved understanding of the underlying molecular pathways responsible for IgAN has led to better therapies targeting novel pathways. The major pharma players currently developing therapies for IgAN include Omeros Corporation (narsoplimab), Novartis Pharmaceuticals (iptacopan), Otsuka Pharmaceutical (sibeprenlimab), RemeGen (telitacicept), and a few others.
To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for IgA Nephropathy. Currently, Travere Therapeutics is leading the therapeutics market with its IgA Nephropathy drug candidates in the most advanced stage of clinical development.
IgA Nephropathy Therapeutic Advancements and Emerging Treatments:
- IgA Nephropathy Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and many others, are actively engaged in developing novel drugs for potential market entry.
- IgA Nephropathy Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of IgA Nephropathy. Some of the emerging therapies in the pipeline include Atrasentan (Chinook Therapeutics), Sparsentan (Travere Therapeutics), Narsoplimab (Omeros Corporation), TARPEYO/ KINPEYGO (budesonide) (Calliditas Therapeutics/STADA/Viatris/Everest Medicines), Iptacopan (Novartis Pharmaceuticals), BION-1301 (Chinook Therapeutics), and others.
Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the IgA Nephropathy Market
IgA Nephropathy Market Growth Factors and Associated Trends
The IgA Nephropathy (IgAN) market within the Seven Major Markets (7MM) is influenced by a complex interplay of drivers and barriers that significantly impact its trajectory. Drivers of growth encompass various factors, including heightened awareness and improved diagnosis rates due to advancements in diagnostic techniques and increased understanding of the disease pathology. Moreover, the rising prevalence of IgA Nephropathy, particularly among the aging population, acts as a catalyst for market expansion. Additionally, ongoing research and development efforts aimed at identifying novel therapeutic targets and treatment modalities drive innovation within the market, offering hope for more effective management of the disease. Furthermore, the evolving treatment landscape, including the exploration of immunosuppressive agents and targeted therapies, fosters market growth by addressing the unmet medical needs of patients with IgA Nephropathy.
However, barriers persist, hindering the market's progress in the 7MM. These barriers encompass challenges in accurately diagnosing IgA Nephropathy due to its diverse clinical presentation and the absence of a definitive diagnostic test. Additionally, limited treatment options and the lack of universally accepted treatment guidelines pose significant hurdles. Moreover, economic factors such as high treatment costs and reimbursement complexities limit patient access to effective therapies. Overcoming these barriers requires concerted efforts in research, improved diagnostic tools, the development of targeted therapies, and advancements in healthcare policies to enhance the management of IgA Nephropathy and foster market growth in the 7MM.
The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for IgA Nephropathy. Moreover, it conducts a thorough evaluation of the factors driving and hindering the IgA Nephropathy market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.
The report meticulously outlines the market trends concerning each marketed IgA Nephropathy drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.
Discover the Anticipated Evolution and Growth of the Market @ IgA Nephropathy Therapeutics Market Forecast
IgA Nephropathy Epidemiology Assessment
The epidemiology section offers valuable insights into the historical, present, and anticipated trends in IgA Nephropathy epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected IgA Nephropathy epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.
The Report Covers the IgA Nephropathy Epidemiology, Segmented as -
- Total Prevalent Cases of IgA Nephropathy in the 7MM [2019-2032]
- Total Diagnosed Prevalent Cases of IgA Nephropathy in the 7MM [2019–2032]
- Gender-specific Cases of IgA Nephropathy in the 7MM [2019-2032]
- Age-specific cases of IgA Nephropathy in the 7MM [2019-2032]
IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the IgA Nephropathy market during the study period. This analysis encompasses the assessment of drug uptake in the IgA Nephropathy market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among IgA Nephropathy drugs, considering their sales performance and respective market shares.
The report encompasses comprehensive coverage of ongoing IgA Nephropathy pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for IgA Nephropathy. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.
Reports Key Features and Analysis
- Study Period - 2019-32
- Forecast Period - 2023-32
- Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
- Market Size (by 2032) and Expected CAGR - Download the Sample PDF
- Major Players Shaping the Market Dynamics - Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and many others.
- Emerging and Marketed Therapies Covered in the Report - Atrasentan (Chinook Therapeutics), Sparsentan (Travere Therapeutics), Narsoplimab (Omeros Corporation), TARPEYO/ KINPEYGO (budesonide) (Calliditas Therapeutics/STADA/Viatris/Everest Medicines), Iptacopan (Novartis Pharmaceuticals), BION-1301 (Chinook Therapeutics), and others.
For In-depth Insights, key Report Offerings TOC, Access the Sample PDF File @ IgA Nephropathy Therapeutics Market Outlook and Forecast
Related Reports:
The IgA Nephropathy Epidemiology Forecast report delivers an in-depth understanding of IgA Nephropathy, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The IgA Nephropathy Pipeline Insight report provides comprehensive insights about major pharma and biotech companies and emerging drugs in the IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Healthcare Consulting and Market Research Services by DelveInsight
Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services
Elevate your market presence and strategy in the medical devices' industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market
DelveInsight's specialized oncology consulting empowers the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at @ Oncology Consulting Services
Discover how our tailored methodology ensures real-time evaluation of cancer therapy performance using Lead and Lag KPIs. Download our Oncology Product Assessment Case study!
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Contact Information:
Shruti Thakur (Manager, Marketing and IB)
info@delveinsight.com
Connect with DelveInsight: LinkedIn | Facebook | Twitter
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
